{"id":"f3b7a388-9f32-520f-9f32-14d746d115f4","stable_key":"ec987f3e-0b3c-55cc-b304-c703a738e35d:egcg-nadolol-rat","predicate":"reduces","statement":"EGCG pretreatment reduced rat nadolol Cmax by 53% and AUC by 51%, with weaker blood-pressure control.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"50ed8435-81bd-5781-98c1-607e50dc0b53","mechanism_event_label":"Purified EGCG also changed nadolol exposure in an animal study.","subject":{"id":"22e1b8eb-f35f-5afa-be20-b0534df9f6be","slug":"egcg","display_name":"Epigallocatechin-3-gallate (EGCG)","entity_type_key":"small_molecule"},"object":{"id":"06d1dce5-9406-5b80-ba0a-30b8386a19c8","slug":"nadolol-plasma-exposure","display_name":"Nadolol plasma exposure","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"50ed8435-81bd-5781-98c1-607e50dc0b53","stable_key":"ec987f3e-0b3c-55cc-b304-c703a738e35d:egcg-nadolol-rat-event","event_type":"observed_relationship","label":"Purified EGCG also changed nadolol exposure in an animal study.","description":"EGCG pretreatment reduced rat nadolol Cmax by 53% and AUC by 51%, with weaker blood-pressure control.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"22e1b8eb-f35f-5afa-be20-b0534df9f6be","slug":"egcg","display_name":"Epigallocatechin-3-gallate (EGCG)","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"06d1dce5-9406-5b80-ba0a-30b8386a19c8","slug":"nadolol-plasma-exposure","display_name":"Nadolol plasma exposure","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"b3604fdc-509f-5137-b727-828a523be7c4","slug":"nadolol","display_name":"Nadolol","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"experimental_model","value_text":"Male spontaneously hypertensive rats; EGCG 10 mg/kg/day for 14 days and nadolol 10 mg/kg on day 14.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Rat transcription/exposure results; mRNA changes do not establish transporter protein activity or a human effect size.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"EGCG collection; comparator and shared-pathway records retain their actual intervention.","comparator":null,"unit":null,"notes":"","entity":{"slug":"egcg","display_name":"Epigallocatechin-3-gallate (EGCG)","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Purified EGCG also changed nadolol exposure in an animal study.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Oral epigallocatechin gallate reduces intestinal nadolol absorption via modulation of Oatp1a5 and Oct1 transcriptional levels in spontaneously hypertensive rats. · 2021 · https://pubmed.ncbi.nlm.nih.gov/34303263/ · DOI 10.1016/j.phymed.2021.153623","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"81736062-780c-5af5-931f-567d14c81d94","evidence_kind":"source_excerpt","locator":"Lines 492-498","start_line":492,"end_line":498,"excerpt":"## egcg-nadolol-rat\nPurified EGCG also changed nadolol exposure in an animal study.\nEGCG pretreatment reduced rat nadolol Cmax by 53% and AUC by 51%, with weaker blood-pressure control.\nModel: Male spontaneously hypertensive rats; EGCG 10 mg/kg/day for 14 days and nadolol 10 mg/kg on day 14.\nLimitations: Rat transcription/exposure results; mRNA changes do not establish transporter protein activity or a human effect size.\nEvidence access: primary abstract.\nOral epigallocatechin gallate reduces intestinal nadolol absorption via modulation of Oatp1a5 and Oct1 transcriptional levels in spontaneously hypertensive rats. · 2021 · https://pubmed.ncbi.nlm.nih.gov/34303263/ · DOI 10.1016/j.phymed.2021.153623","model_system":"Male spontaneously hypertensive rats; EGCG 10 mg/kg/day for 14 days and nadolol 10 mg/kg on day 14.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Primary-abstract paraphrase; no full-text methods verification claimed.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"1f6d09e8-3aae-5c41-9ea7-15d0d1cab72d","stable_key":"import-ec987f3e-0b3c-55cc-b304-c703a738e35d","title":"EGCG: receptor signaling, metabolism, nutrient interactions and discovery questions (2026-09-18)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"b101c8d4d96ee03ff97eb1922c7bb0f96943295af473fdc3ef98b0dbd62fe8c7","revision_id":"e19bc5b2-ee3c-5f67-b5c5-9dc3b7d5f850","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}